Introgen’s Advexin Doubles Survival In Some Head & Neck Cancer Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm plans end-of-June filing in U.S. and EU for p53 tumor suppressor in recurrent head and neck cancer.